Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
DCGen
The company provides a breast cancer prognosis prediction kit.
Sector
Subsector
Keywords
Location
total rounds
Paradigm Diagnostics
Paradigm provides advanced diagnostics and personalized treatment options to cancer patients.
Sector
Subsector
Location
total rounds
total raised
Cambridge Cancer Genomics
Cambridge Cancer Genomics develops precision oncology solutions to transform cancer treatment.
Sector
Subsector
Keywords
Location
total rounds
total raised
Molecular Match
Molecular Match is a health and wellness company that uses proprietary algorithms to match cancer patients with appropriate therapies.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds9
Number of Funding Rounds
Money Raised
Their latest funding was raised on 25.07.2018. Their latest investor Gilde Healthcare. Their latest round Private Equity
Athyrium Capital Management, LP
Athyrium Capital Management, LP is a private equity firm specializing in global healthcare sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Norgine Ventures
Norgine Ventures is a healthcare-focused venture capital firm in the UK.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors10
Number of lead investors
Number of investors
Gilde Healthcare
Gilde Healthcare is a European healthcare investor that specializes in lower mid-market buyouts and later stage venture.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Pieter van der Meer
Pieter van der Meer joined Gilde in 1998 following a consultant position with KPMG Management Consulting in the Netherlands. At KPMG, Pieter was involved with due diligence and strategic projects within various sectors. Pieter van der Meer was a member of the Working Group of the Dutch Participation Association (NVP), advising the Ministry of Economic Affairs on policy to stimulate early stage venture creation. He is a member of the project screening committees at Dutch Universities. He holds a master degree in Chemistry from Leiden University, specializing in bio-organic synthesis and molecular modeling. Pieter van der Meer is a Dutch national and speaks English and Spanish. He led investments in Ablynx, Acacia Pharma, Agendia, Inpharmatica and BG Medicine. He represented Gilde on the board of Ablynx and is currently on the boards of Acacia Pharma, Agendia and BG Medicine.
current job
ING Corporate Investments
ING Corporate Investments invests in small and medium size enterprises.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Van Herk Ventures
Van Herk Ventures invests in life sciences through direct investments in private and listed companies, as well as venture capital funds.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders3
Laura Johanna van 't Veer
Prof. Dr. Laura van ’t Veer is Chief Research Officer of Agendia and a co-founder of the Company. Laura has a 20-year track record in molecular oncology research with more than 100 published papers. In 2010, Laura was appointed to the prestigious position of professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco (UCSF) and is currently head of the Netherlands Cancer Insitiue (NKI) DNA-diagnostic laboratory and a staff member in the Department of Molecular Pathology.
current job
organization founded
Laura Johanna van 't Veer
Rene Bernards
Rene Bernards brings extensive experience in oncology as a researcher and entrepreneur. He received his PhD in 1984 from the University of Leiden. He performed his post-doctoral research at the Massachusetts Institute of Technology in Robert Weinberg’s group at the Whitehead Institute. He joined Harvard University as an assistant professor in 1988 to study function of oncogenes and tumor suppressor genes. In 1992 he was appointed senior staff scientist at the Netherlands Cancer Institute where he studies mammalian cancer genetics. In 1994 he was appointed part time professor of molecular carcinogenesis at Utrecht University, The Netherlands. His laboratory focuses on the development of new tools to perform genome-wide genetic screens to identify novel genes that act in cancer relevant pathways. He was a co-founder of Prolifix in 1993 (currently TopoTarget) and co-founded Agendia in 2003, for which he also acts as scientific director. He assists in the evaluation of investment opportunities.
current job
Rene Bernards
Employee Profiles64
S. Roopom Banerjee
Chief Strategy Officer, Head of Business Development & Financing
Dominic Weilbaecher
National director, managed care
Activity
Recent News12
The graph reveals the ratio (%) of positive news articles in a chosen time range